2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The use of anthracycline-based chemotherapy is associated with the development of heart failure, even years after the end of treatment. Early detection of cardiac dysfunction could identify a high-risk subset of survivors who would eventually benefit from early intervention. Cardiac magnetic resonance feature-tracking (CMR-FT) analysis offers a practical and rapid method to calculate systolic and diastolic strains from routinely acquired cine images. While early changes in systolic function have been described, less data are available about late effects of chemotherapy in diastolic parameters by CMR-FT. The main goal of this study was to determine whether left ventricular (LV) early diastolic strain rates (GDSR-E) by CMR-FT are impaired in long-term adult survivors of non-Hodgkin lymphoma (NHL). Our secondary objective was to analyze associations between GDSR-E with cumulative anthracycline dose, systolic function parameters and myocardial tissue characteristics.

          Methods

          This is a single center cross-sectional observational study of asymptomatic patients in remission of NHL who previously received anthracycline therapy. All participants underwent their CMR examination on a 3.0-T scanner, including cines, T2 mapping, T1 mapping and late gadolinium enhancement imaging. Derived myocardial extracellular volume fraction was obtained from pre- and post-contrast T1 maps. CMR-FT analysis was performed using Trufi Strain software. The data obtained were compared between anthracycline group and volunteers without cardiovascular disease or neoplasia.

          Results

          A total of 18 adult survivors of NHL, 14 (77.8%) males, at mean age of 57.6 (± 14.7) years-old, were studied 88.2 (± 52.1) months after exposure to anthracycline therapy (median 400 mg/m 2). Compared with controls, anthracycline group showed impaired LV global early diastolic circumferential strain rate (GCSR-E) [53.5%/s ± 19.3 vs 72.2%/s ± 26.7, p = 0.022], early diastolic longitudinal strain rate (GLSR-E) [40.4%/s ± 13.0 vs 55.9%/s ± 17.8, p = 0.006] and early diastolic radial strain rate (GRSR-E) [− 114.4%/s ± 37.1 vs − 170.5%/s ± 48.0, p < 0.001]. Impaired LV GCSR-E, GLSR-E and GRSR-E correlated with increased anthracycline dose and decreased systolic function. There were no correlations between GDSR-E and myocardial tissue characteristics.

          Conclusions

          Left ventricular early diastolic strain rates by CMR-FT are impaired late after anthracycline chemotherapy in adult survivors of non-Hodgkin lymphoma.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: not found
          • Article: not found

          2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)

            Parametric mapping techniques provide a non-invasive tool for quantifying tissue alterations in myocardial disease in those eligible for cardiovascular magnetic resonance (CMR). Parametric mapping with CMR now permits the routine spatial visualization and quantification of changes in myocardial composition based on changes in T1, T2, and T2*(star) relaxation times and extracellular volume (ECV). These changes include specific disease pathways related to mainly intracellular disturbances of the cardiomyocyte (e.g., iron overload, or glycosphingolipid accumulation in Anderson-Fabry disease); extracellular disturbances in the myocardial interstitium (e.g., myocardial fibrosis or cardiac amyloidosis from accumulation of collagen or amyloid proteins, respectively); or both (myocardial edema with increased intracellular and/or extracellular water). Parametric mapping promises improvements in patient care through advances in quantitative diagnostics, inter- and intra-patient comparability, and relatedly improvements in treatment. There is a multitude of technical approaches and potential applications. This document provides a summary of the existing evidence for the clinical value of parametric mapping in the heart as of mid 2017, and gives recommendations for practical use in different clinical scenarios for scientists, clinicians, and CMR manufacturers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

              Three types of anthracycline-induced cardiotoxicities are currently recognized: acute, early-onset chronic, and late-onset chronic. However, data supporting this classification are lacking. We prospectively evaluated incidence, time of occurrence, clinical correlates, and response to heart failure therapy of cardiotoxicity.
                Bookmark

                Author and article information

                Contributors
                maufbarbosa@gmail.com
                Journal
                BMC Cardiovasc Disord
                BMC Cardiovasc Disord
                BMC Cardiovascular Disorders
                BioMed Central (London )
                1471-2261
                12 April 2021
                12 April 2021
                2021
                : 21
                : 170
                Affiliations
                [1 ]GRID grid.411249.b, ISNI 0000 0001 0514 7202, Department of Diagnostic Imaging, , Universidade Federal de São Paulo (UNIFESP), ; Rua Napoleão de Barros 800, Vila Clementino, São Paulo, 04024-002 Brazil
                [2 ]GRID grid.410543.7, ISNI 0000 0001 2188 478X, Department of Tropical Diseases and Diagnostic Imaging, , Universidade Estadual Paulista (UNESP), ; Botucatu, Brazil
                [3 ]GRID grid.410543.7, ISNI 0000 0001 2188 478X, Cardiology Division, Internal Medicine Department, , Universidade Estadual Paulista (UNESP), ; Botucatu, Brazil
                [4 ]GRID grid.410543.7, ISNI 0000 0001 2188 478X, Hematology Division, Internal Medicine Department, , Universidade Estadual Paulista (UNESP), ; Botucatu, Brazil
                [5 ]GRID grid.4991.5, ISNI 0000 0004 1936 8948, University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), , University of Oxford, ; Oxford, UK
                [6 ]GRID grid.410543.7, ISNI 0000 0001 2188 478X, Pneumology Division, Internal Medicine Department, , Universidade Estadual Paulista (UNESP), ; Botucatu, Brazil
                [7 ]GRID grid.410543.7, ISNI 0000 0001 2188 478X, Department of Physical Education, , Universidade Estadual Paulista (UNESP), ; Presidente Prudente, Brazil
                [8 ]GRID grid.413562.7, ISNI 0000 0001 0385 1941, Hospital Israelita Albert Einstein, ; São Paulo, Brazil
                Author information
                http://orcid.org/0000-0002-6557-2275
                http://orcid.org/0000-0002-9456-0150
                http://orcid.org/0000-0002-9480-4995
                http://orcid.org/0000-0002-2334-2359
                http://orcid.org/0000-0002-2587-2759
                http://orcid.org/0000-0003-1576-8090
                http://orcid.org/0000-0003-0732-2814
                http://orcid.org/0000-0002-1941-7899
                Article
                1996
                10.1186/s12872-021-01996-6
                8040217
                33845778
                4cb49292-b320-4053-9e63-e0e78886d115
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 7 January 2021
                : 7 April 2021
                Categories
                Research
                Custom metadata
                © The Author(s) 2021

                Cardiovascular Medicine
                strain,feature-tracking,diastolic dysfunction,cancer,chemotherapy
                Cardiovascular Medicine
                strain, feature-tracking, diastolic dysfunction, cancer, chemotherapy

                Comments

                Comment on this article